# A Long-Term Safety Extension Trial of Ferric Citrate in Patients With End-Stage Renal Disease (ESRD) on Dialysis

> **NCT01554982** · PHASE3 · COMPLETED · sponsor: **Keryx Biopharmaceuticals** · enrollment: 168 (actual)

## Conditions studied

- End Stage Renal Disease
- Kidney Failure
- Renal Failure
- Hyperphosphatemia
- ESRD

## Interventions

- **DRUG:** ferric citrate

## Key facts

- **NCT ID:** NCT01554982
- **Lead sponsor:** Keryx Biopharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-08
- **Primary completion:** 2014-06
- **Final completion:** 2014-08
- **Target enrollment:** 168 (ACTUAL)
- **Last updated:** 2016-07-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01554982

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01554982, "A Long-Term Safety Extension Trial of Ferric Citrate in Patients With End-Stage Renal Disease (ESRD) on Dialysis". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT01554982. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*